MarketPeel
Insider Trading Intelligence
Pricing
…
AL

Adar1 Capital Management, Llc

KROS
10% OWNER · KEROS THERAPEUTICS, INC. · CIK 0001940272
FILING MIX · LIFETIME59%/41%
BUYS
22
SELLS
15
TOTAL VALUE
$110.19M
COMPANIES
3
ACTIVE SINCE
Apr 2025
HOLDINGS NOW
1,726,352
AVG SELL PX
$17.77
TRADE KIND
SHOWING 37 / 37
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
14 backtested trades · 8 horizons · 38 pending
Forward-return performance of every backtestable P/S trade by Adar1 Capital Management, Llc, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d14+57.14%+12.54%-0.85%+14.31%+6.99%—
14d14+57.14%+16.78%+0.48%+19.85%+20.65%—
30d14+76.92%+20.61%+1.37%+22.55%+18.10%—
60d14(3 pending)+72.73%+32.63%+5.81%+26.82%+27.09%—
90d14(6 pending)+62.50%+34.63%+9.78%+24.84%+21.58%—
180d14(6 pending)+100.00%+23.36%+15.19%+8.17%+28.79%—
1y14(9 pending)+100.00%+20.91%+23.93%-3.02%-3.02%—
2y14(14 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KROS · 0 shares · as of Oct 15, 2025
01,098,1842,196,3693,294,5534,392,737SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2025
2025
2025
2026
2026
FLOW · 22 buys / 15 sellsCOVERAGE · 5 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
RLYB
RALLYBIO CORP
PURCHASE
10,000$13.98$139.8K926,152May 19, 2026May 20, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
200$13.80$2.8K926,352May 19, 2026May 20, 2026 ↗View →
INM
INMED PHARMACEUTICALS INC.
PURCHASE
200,000$1.56$312.1K600,000May 19, 2026May 21, 2026 ↗View →
INM
INMED PHARMACEUTICALS INC.
PURCHASE
68,551$1.60$109.7K400,000May 19, 2026May 21, 2026 ↗View →
INM
INMED PHARMACEUTICALS INC.
PURCHASE
200,000$1.50$299.8K800,000May 19, 2026May 21, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
6,009$13.98$84.0K916,152May 18, 2026May 20, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
200$13.95$2.8K910,143May 15, 2026May 15, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
100$13.80$1.4K909,943May 15, 2026May 15, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
4,081$13.80$56.3K834,665May 13, 2026May 15, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
75,178$14.00$1.05M909,843May 13, 2026May 15, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
800$13.83$11.1K830,584May 12, 2026May 13, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
19,900$14.00$278.6K829,784May 11, 2026May 13, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
5,100$14.00$71.4K784,884May 11, 2026May 13, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
25,000$14.00$350.0K809,884May 11, 2026May 13, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
35,101$14.00$491.3K779,784May 5, 2026May 6, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
116,904$13.97$1.63M744,683May 4, 2026May 6, 2026 ↗View →
RLYB
RALLYBIO CORP
PURCHASE
3,900$13.90$54.2K627,779May 4, 2026May 6, 2026 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
4,391,237$17.75$77.94M0Oct 15, 2025Oct 15, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
743,358$17.75$13.19M0Oct 15, 2025Oct 15, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
254,669$17.75$4.52M0Oct 15, 2025Oct 15, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
200$70.00$14.0K743,358Jun 20, 2025Jun 24, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
2——0Jun 20, 2025Jun 24, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
1——0Jun 20, 2025Jun 24, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
100$60.00$6.0K4,392,637Jun 20, 2025Jun 24, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
14——0Jun 20, 2025Jun 24, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
1,400$70.00$98.0K4,391,237Jun 20, 2025Jun 24, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
178——0May 16, 2025Jun 12, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
300——0May 16, 2025Jun 12, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
836——0May 16, 2025Jun 12, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
PURCHASE
18,560$9.40$174.4K3,493,404Apr 9, 2025Apr 11, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
74,333——50,000Apr 9, 2025Apr 11, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
PURCHASE
16,365$9.40$153.8K743,558Apr 9, 2025Apr 11, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
PURCHASE
74,333$10.33$767.9K4,392,737Apr 9, 2025Apr 11, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
500,000——124,333Apr 9, 2025Apr 11, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
PURCHASE
500,000$10.33$5.17M4,318,404Apr 9, 2025Apr 11, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
SALE
325,000——624,333Apr 9, 2025Apr 11, 2025 ↗View →
KROS
KEROS THERAPEUTICS, INC.
PURCHASE
325,000$9.86$3.20M3,818,404Apr 9, 2025Apr 11, 2025 ↗View →
Other insiders · KROS
Loading peer insiders…
About this filer
CIK 0001940272
ROLE
10% Owner
PRIMARY
KROS
COMPANIES
3
ACTIVE SINCE
Apr 2025
MARKETPEEL · /INSIDER/0001940272DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback